Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of CM512 in chronic rhinosinusitis with nasal polyps
CTR20263389Phase 3Active
- Sponsor
- Keymed Biosciences
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CM512 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Keymed Biosciences. Started Sep 2026; status: active.
02
Drugs
CM512
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20263389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263389.